Quantcast

Scion Medical Technologies Receives FDA 510 (k) Clearance for The Cassi™ Beacon™ Tissue Marker

June 3, 2013

Scion Medical announces the introduction of Cassi Beacon, a breast biopsy tissue marker which provides excellent and permanent visualization ultrasound and other major imaging modalities.

Newton, MA (PRWEB) June 03, 2013

Scion Medical Technologies, LLC announces the introduction of the Cassi Beacon tissue marker, the company´s newest addition to the Cassi breast biopsy product portfolio.

The Cassi Beacon tissue marker is a single use marker which is placed into soft tissue during breast biopsy procedures to radiographically mark a surgical site for easy location during a surgical procedure or for future procedures. The marker provides excellent and permanent visualization under the major imaging modalities; ultrasound, x-ray, mammography, and MRI. The Beacon is the first breast biopsy marker to use Polyetherketoneketone (PEKK) Polymers which are used routinely in surgical implants and dental devices.

“We are very excited about the introduction of the Beacon tissue marker to the Cassi family of biopsy products. Beacon was developed based on physician feedback for improved and permanent marker visibility under ultrasound imaging. We are pleased to offer doctors this innovative tool for the management of their breast cancer patients.” — Joseph Siletto, CEO

The Cassi Beacon tissue marker is now available and additional information can be found at http://www.scionmedtech.com.

About Scion Medical Technologies:

Scion Medical Technologies (Scion) is a global medical device company with US headquarters in Massachusetts. Scion has manufacturing, distribution and regulatory expertise in the US and China, and is actively looking to grow its product portfolio by acquiring and licensing medical devices that have received 510(k) clearance or premarket approval from the FDA, or are CE-Marked.

Contact:

Scion Medical Technologies| Kristen Marcinelli | Kristen(at)scionmedtech(dot)com

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10781271.htm


Source: prweb



comments powered by Disqus